Prime Genomics

Prime Genomics is developing new biofluid-based molecular diagnostic tests, which will make breast cancer detection more accurate, efficient, accessible, and affordable for women anywhere. The company’s team consists of accomplished innovators in the fields of molecular diagnostics, genomics, and advanced data science, who believe that breakthrough transformations in healthcare are possible. Prime Genomics' non-invasive biofluid advantages include: suitability for all women, including approximately 50% with dense breast tissue who are underserved by imaging; more precise detection that eliminates millions of follow-up appointments and invasive procedures; streamlining multi-step processes to reduce false positives, delays, and patient anxiety; and a truly non-invasive test that increases access and compliance while helping address current disparities in care.